沙美特罗替卡松联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的临床效果

Clinical efficacy of salmeterol fluticasone propionate combined with tiotropium bromide in the treatment of asthma-COPD overlap syndrome

目的探讨沙美特罗替卡松联合噻托溴铵治疗哮喘-慢阻肺重叠综合征(ACOS)的临床效果。方法将90例ACOS患者按治疗方法不同分为试验组(沙美特罗替卡松+噻托溴铵)和对照组(沙美特罗替卡松),各45例。比较两组的临床效果。结果试验组的治疗总有效率高于对照组(P<0.05);治疗后,两组的FEV1、RV/TLC、IC/TLC、急性加重次数和生活质量评分均改善,且试验组均优于对照组(P<0.05);两组均未出现严重不良反应。结论沙美特罗替卡松联合噻托溴铵治疗ACOS,临床疗效显著,可明显改善患者的肺功能,减少急性发作,提高患者生活质量。

Objective To investigate the clinical efficacy of salmeterol fluticasone propionate combined with tiotropiumbromide in the treatment of asthma-COPD overlap syndrome （ACOS）. Methods Ninety patients with ACOS were dividedinto experimental group （salmeterol fluticasone propionate＋tiotropium bromide） and control group （salmeterol fluticasonepropionate） according to different treatment methods, with 45 cases in each group. The clinical effects of the two groupswere compared. Results The total effective rate of treatment in the experimental group was higher than that in the controlgroup（P〈0.05）. After treatment, the FEV1, RV/TLC, IC/TLC, times of acute exacerbation and scores of quality of life in thetwo groups improved, and those in the experimental group were better than the control group（P〈0.05）. No serious adversereactions occurred in the two groups. Conclusion The salmeterol fluticasone propionate combined with tiotropium bromidein the treatment of ACOS has significant clinical efficacy, which can significantly improve the lung function of patients,reduce acute exacerbations, and improve the quality of life of patients.